Literature DB >> 25657199

The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.

Yoshikazu Hasegawa1, Masahiko Ando2, Makoto Maemondo1, Satomi Yamamoto1, Shun-Ichi Isa1, Hideo Saka1, Akihito Kubo1, Tomoya Kawaguchi1, Minoru Takada1, Rafael Rosell1, Takayasu Kurata1, Sai-Hong Ignatius Ou2.   

Abstract

BACKGROUND: Univariate analyses from several randomized phase III trials seemed to suggest ever-smokers with advanced mutated epidermal growth factor receptor (EGFRm) non-small cell lung cancer (NSCLC) did not seem to benefit from EGFR tyrosine kinase inhibitors (TKIs) as first-line treatment when compared with platinum-doublet chemotherapy as measured by progression-free survival (PFS).
METHODS: A literature-based meta-analysis of PFS outcomes as measured by log-transformed pooled hazard ratio (HR) was performed using a random-effect model. Pooled HRs for smoking status, age, gender, ethnicity, type of EGFR mutation, and EGFR TKI were obtained. Comparison of the pooled HR was performed by metaregression analysis.
RESULTS: Among the 1,649 EGFRm NSCLC patients analyzed from 7 prospective randomized trials (WJTOG3405, NEJ002, EURTAC, OPTIMAL, LUX Lung-3, LUX Lung-6, and ENSURE), 83.7% were Asians, and 30.0% were ever-smokers. An equal percentage of ever-smokers received doublet chemotherapy (30.2%) or EGFR TKI (30.0%). The pooled HR for PFS was 0.29 (95% confidence interval [CI]: 0.21-0.39) for never-smokers and 0.54 (95% CI: 0.38-0.76) for ever-smokers (p < .007 by metaregression). The pooled PFS HR for exon 19 deletion was 0.25 (95% CI: 0.19-0.31) and 0.44 for exon 21 substitution (95% CI: 0.34-0.57) (p < .001 by metaregression analysis). The pooled PFS HR was 0.33 (95% CI: 0.24-0.46) for Asians and 0.48 for non-Asians (95% CI: 0.28-0.84) (p = .261 by metaregression analysis).
CONCLUSION: EGFRm NSCLC patients derived significant PFS benefit from TKI over platinum-doublet chemotherapy as first-line treatment regardless of smoking status; however, PFS benefit is significantly better in never-smokers by metaregression analysis. ©AlphaMed Press.

Entities:  

Keywords:  Afatinib; EGFR TKIs; EGFR mutant non-small cell lung cancer; Erlotinib; Gefitinib; Meta-analysis; Smoking status

Mesh：

Substances：

Year:  2015        PMID： 25657199      PMCID： PMC4350797          DOI： 10.1634/theoncologist.2014-0285

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  25 in total

1.  First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Authors:  Ji-Youn Han; Keunchil Park; Sang-We Kim; Dae Ho Lee; Hyae Young Kim; Heung Tae Kim; Myung Ju Ahn; Tak Yun; Jin Seok Ahn; Cheolwon Suh; Jung-Shin Lee; Sung Jin Yoon; Jong Hee Han; Jae Won Lee; Sook Jung Jo; Jin Soo Lee
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

2.  Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells.

Authors:  Shuo Wang; Koichi Takayama; Kentaro Tanaka; Masafumi Takeshita; Noriaki Nakagaki; Kayo Ijichi; Heyan Li; Yoichi Nakanishi
Journal:  J Thorac Oncol       Date:  2013-06       Impact factor: 15.609

3.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Authors:  Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lu; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; Li Zhang; Changxuan You
Journal:  Lancet Oncol       Date:  2011-07-23       Impact factor: 41.316

4.  Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

Authors:  A Inoue; K Kobayashi; M Maemondo; S Sugawara; S Oizumi; H Isobe; A Gemma; M Harada; H Yoshizawa; I Kinoshita; Y Fujita; S Okinaga; H Hirano; K Yoshimori; T Harada; Y Saijo; K Hagiwara; S Morita; T Nukiwa
Journal:  Ann Oncol       Date:  2012-09-11       Impact factor: 32.976

5.  Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells.

Authors:  Simone Filosto; David S Baston; Samuel Chung; Cathleen R Becker; Tzipora Goldkorn
Journal:  Mol Cancer Ther       Date:  2013-05-17       Impact factor: 6.261

6.  Genomic landscape of non-small cell lung cancer in smokers and never-smokers.

Authors:  Ramaswamy Govindan; Li Ding; Malachi Griffith; Janakiraman Subramanian; Nathan D Dees; Krishna L Kanchi; Christopher A Maher; Robert Fulton; Lucinda Fulton; John Wallis; Ken Chen; Jason Walker; Sandra McDonald; Ron Bose; David Ornitz; Donghai Xiong; Ming You; David J Dooling; Mark Watson; Elaine R Mardis; Richard K Wilson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

7.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

8.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

Review 9.  Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?

Authors:  Sai-Hong Ignatius Ou
Journal:  J Clin Pathol       Date:  2013-05-09       Impact factor: 3.411

10.  Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients.

Authors:  Chong-Kin Liam; Mohamed Ibrahim A Wahid; Pathmanathan Rajadurai; Yoke-Kqueen Cheah; Tiffany Shi-Yeen Ng
Journal:  J Thorac Oncol       Date:  2013-06       Impact factor: 15.609
View more
  29 in total

1.  Prediagnostic Calcium Intake and Lung Cancer Survival: A Pooled Analysis of 12 Cohort Studies.

Authors:  Danxia Yu; Yumie Takata; Stephanie A Smith-Warner; William Blot; Norie Sawada; Emily White; Neal Freedman; Kim Robien; Edward Giovannucci; Xuehong Zhang; Yikyung Park; Yu-Tang Gao; Rowan T Chlebowski; Arnulf Langhammer; Gong Yang; Gianluca Severi; Jonas Manjer; Kay-Tee Khaw; Elisabete Weiderpass; Linda M Liao; Neil Caporaso; Steinar Krokstad; Kristian Hveem; Rashmi Sinha; Regina Ziegler; Shoichiro Tsugane; Yong-Bing Xiang; Mattias Johansson; Wei Zheng; Xiao-Ou Shu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-03-06       Impact factor: 4.254

2.  The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.

Authors:  Yoon Ki Cha; Ho Yun Lee; Myung-Ju Ahn; Keunchil Park; Jin Seok Ahn; Jong-Mu Sun; Yoon-La Choi; Kyung Soo Lee
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 3.  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Authors:  D Westover; J Zugazagoitia; B C Cho; C M Lovly; L Paz-Ares
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

4.  A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR-mutated lung adenocarcinoma.

Authors:  Y Cao; H Xu
Journal:  Curr Oncol       Date:  2018-04-30       Impact factor: 3.677

5.  First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

Authors:  Janette Greenhalgh; Angela Boland; Victoria Bates; Fabio Vecchio; Yenal Dundar; Marty Chaplin; John A Green
Journal:  Cochrane Database Syst Rev       Date:  2021-03-18

6.  Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.

Authors:  Emilio Bria; Sara Pilotto; Eliana Amato; Matteo Fassan; Silvia Novello; Umberto Peretti; Tiziana Vavalà; Stefania Kinspergher; Luisella Righi; Antonio Santo; Matteo Brunelli; Vincenzo Corbo; Eliana Giglioli; Isabella Sperduti; Michele Milella; Marco Chilosi; Aldo Scarpa; Giampaolo Tortora
Journal:  Oncotarget       Date:  2015-05-20

7.  EGFR mutation, smoking, and gender in advanced lung adenocarcinoma.

Authors:  Chien-Hua Tseng; Chun-Ju Chiang; Jeng-Sen Tseng; Tsung-Ying Yang; Kuo-Hsuan Hsu; Kun-Chieh Chen; Chih-Liang Wang; Chih-Yi Chen; Sang-Hue Yen; Chun-Ming Tsai; Ming-Shyan Huang; Chao-Chi Ho; Chong-Jen Yu; Ying-Huang Tsai; Jin-Shing Chen; Teh-Ying Chou; Ming-Hsun Tsai; Hsuan-Yu Chen; Kang-Yi Su; Jeremy J W Chen; Huei-Wen Chen; Sung-Liang Yu; Tsang-Wu Liu; Gee-Chen Chang
Journal:  Oncotarget       Date:  2017-10-12

8.  Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.

Authors:  R-L Chen; H-J Chen; B-Y Jiang; X-C Zhang; Q Zhou; H-Y Tu; W-Z Zhong; Y-L Wu; J-J Yang
Journal:  Clin Transl Oncol       Date:  2017-07-12       Impact factor: 3.405

Review 9.  Tyrosine Kinase Inhibitors for the Elderly.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Michael Steinheimer; Naim Benhassen; Theodora Tsiouda; Sofia Baka; Lonny Yarmus; Grigoris Stratakos; John Organtzis; Athanasia Pataka; Kosmas Tsakiridis; Ilias Karapantzos; Chrysanthi Karapantzou; Kaid Darwiche; Athanasios Zissimopoulos; Georgia Pitsiou; Konstantinos Zarogoulidis; Yan-Gao Man; Harald Rittger
Journal:  J Cancer       Date:  2016-03-21       Impact factor: 4.207

Review 10.  Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations.

Authors:  Jun Wang; Baocheng Wang; Huili Chu; Yunfeng Yao
Journal:  Onco Targets Ther       Date:  2016-06-22       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.